Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53

1 Jan 2013

Abstract excerpt

Serous uterine endometrial carcinomas are aggressive type II cancers with poor outcomes for which new treatment strategies are urgently needed, in particular, strategies that augment sensitivity to established chemotherapy regimens. The tumor suppressor gene TP53 is dysregulated in more than 90% of serous tumors, altering master regulators of the G2/M cell cycle checkpoint in unique and predictable ways and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Endometrial and Cervical Cancer Treatments
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24381593
DOI: 10.1155/2013/828165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53PMID 24381593Read ↗

Synthetically lethal nanoparticles for treatment of endometrial cancer.Semantic proximity Read ↗

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategySemantic proximity Read ↗

Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 MutationsSemantic proximity Read ↗

A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant CancersSemantic proximity Read ↗

P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathwaySemantic proximity Read ↗

Updates in therapy for uterine serous carcinomaSemantic proximity Read ↗

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapySemantic proximity Read ↗

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Semantic proximity Read ↗

Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Semantic proximity Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.Semantic proximity Read ↗

MAP kinase ERK5 modulates cancer cell sensitivity to extrinsic apoptosis induced by death-receptor agonists and Natural Killer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.